14,02 $US-5,5 %clôture 13 nov.
Chiffres jusqu’au 30 septembre 2026, issus du 10-Q déposé le 12 novembre 2026
D’après le 8-K de l’entreprise.
BlossomHill Therapeutics, Inc. reported on 12 novembre 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We are pleased to have aligned with the FDA on a recommended Phase 2 dose of 50 mg BID based on favorable PK, safety and efficacy data in the Phase 1 portion of the SOLARA trial. We are now preparing to initiate SOLARA-2, a single arm, pivotal Phase 2 trial designed to evaluate BH-30643 in both chemotherapy-naive and chemotherapy-pretreated patients with C797S-positive NSCLC after progression on a third-generation EGFR TKI,”
Cité mot pour mot du communiqué, et affiché uniquement lorsque le document l’attribue à une personne nommée.
Les communiqués tombent avant l’ouverture ou après la clôture : la fenêtre va donc de la clôture précédant le jour du communiqué à la clôture de la séance suivante, et contient la réaction dans les deux cas.
BH-30643 is an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective, OMNI-EGFR inhibitor for the treatment of EGFR -mutant NSCLC. BH-30643 was designed to overcome the limitations of currently approved EGFR inhibitors, which were discovered over a decade ago without the current, modern understanding of the structure and protein dynamics of mutant EGFRs. In preclinical studies, BH-30643 demonstrated potent inhibitory activity across diverse EGFR mutation categories — classical mutations, on-target resistance mutations such as C797S with or without T790M, atypical mutations and exon 20 insertions — while maintaining marked selectivity over wild-type EGFR. BH-30643 has received Fast Track designation and is being evaluated in SOLARA, a global Phase 1/2, first-in-human clinical trial with ongoing Phase 1 dose expansion cohorts enrolling in both TKI-pretreated and TKI-naive settings, including a C797S resistance cohort. SOLARA-2, a global Phase 2 pivotal study in C797S-Positive NSCLC is scheduled to dose the first patient in the first quarter of 2027. For additional information on SOLARA, including a list of study sites and how to enroll, please visit clinicaltrials.gov ( NCT06706076 ).
La description que l’entreprise donne d’elle-même, telle qu’elle figure au bas du communiqué.
La citation et la description de l’entreprise proviennent du 8-K au titre de l’item 2.02 déposé par BlossomHill Therapeutics, Inc. le 12 novembre 2026 ; le tableau est établi à partir de ses rapports trimestriels. Lire le communiqué sur EDGAR Les cours sont ajustés des divisions d’actions et des dividendes.